Smart + Strong.
All Rights Reserved.
Smart + Strong®
is a registered trademark of CDM Publishing, LLC.
In 2018, Black and Latino patients with advanced cirrhosis had a higher risk of mortality compared with white people.
Drug-related mortality, including overdose, was the leading cause of death.
Restoration of gut function and microbial diversity could lead to improvement of hepatic encephalopathy.
People who are living with all three viruses have a greater likelihood of progressing to end-stage liver disease.
Better results were observed even in people with increased portal hypertension.
People treated with direct-acting antivirals had a lower risk for liver failure and liver cancer as well as much lower mortality.
Less than 10% of people with cirrhosis were regularly monitored for liver cancer.
However, some 10% experienced liver decompensation even after antiviral therapy.
Some experts have doubted the link between sustained virologic response and clinical outcomes.
Scientists have firmly established an association between direct-acting antiviral treatment and a lower risk of liver cancer and death.
You have been inactive for 60 minutes and will be logged out in . Any updates not saved will be lost.
Click here to log back in.